BRIEF—Mundipharma launches Invokana and Vokanamet in Norway

Mundipharma has now launched Invokana (canagliflozin) and Vokanamet (canagliflozin, metformin), two treatment options for the management of type 2 diabetes, in Norway.

Mundipharma now exclusively distributes these treatments across the whole of Scandinavia, and a total of 18 markets in Europe as part of the exclusive distribution agreement with Janssen, a unit of Johnson & Johnson.

Approximately 58 million people in Europe currently live with the condition, which is on the rise and predicted to affect 67 million people by 2045. If left untreated, patients are at greater risk of developing serious complications, such as cardiovascular disease and kidney failure.

Invokana and Vokanamet have both shown improvement in glycemic control and reduction of cardiovascular morbidity, as well as improvements in renal outcomes.

Further data investigating canagliflozin for renal protection will be presented during the late-breaker session at the World Congress of Nephrology on April 15.